Cheng M Liu

US Patent:

20140031049, Jan 30, 2014

Filed:

Jul 25, 2013

Appl. No.:

13/951396

Inventors:

Cheng Liu - Princeton NJ, US
Mustafa Arslan - Princeton NJ, US
Meilong Jiang - Princeton NJ, US
Sampath Rangarajan - Princeton NJ, US

Assignee:

NEC Laboratories America, Inc. - Princeton NJ

International Classification:

H04W 16/02
H04W 84/04

US Classification:

455447, 455446

Abstract:

A wireless communications system is disclosed. The system comprises a baseband processing unit (BBU) pool including one or more baseband processing units (BBUs), and a plurality of remote radio heads (RRHs) connected to the BBU pool through a front-haul network, wherein the wireless communications system has a plurality of sectors, each of which includes one or more small cells, each of which is deployed by one of the plurality of RRHs, wherein a BBUs is mapped to two or more RRHs in a sector in a one-to-many configuration, and a BBU is mapped to a single RRH in a sector in a one-to-one configuration, and wherein a combination of the one-to-one configuration and the one-to-many configuration is applied to each sector. Other systems, apparatuses, and methods also are disclosed.

US Patent:

20200115470, Apr 16, 2020

Filed:

Oct 28, 2019

Appl. No.:

16/665708

Inventors:

- New York NY, US
- Emeryville CA, US
Andres Lopez-Albaitero - New York NY, US
Cheng Liu - Emeryville CA, US
Su Yan - State College PA, US
Jingyi Xiang - Walnut Creek CA, US
Hong Liu - El Sobrante CA, US

International Classification:

C07K 16/46
G01N 33/68
C07K 16/28
C07K 16/08

Abstract:

Described herein are antibodies, fragments thereof and multi-specific binding agents that bind an Epstein-Barr virus (EBV) latent membrane protein 2 (LMP2) peptide presented by HLA class I molecules, in particular, HLA-A02. Also provided herein are methods of using the same or compositions thereof for the detection, prevention and/or therapeutic treatment of diseases characterized by expression of an EBV-LMP2 peptide presented by HLA-A02, in particular, Burkit's lymphoma, Hodgkin's lymphoma and nasopharyngeal carcinoma.

US Patent:

20180258187, Sep 13, 2018

Filed:

Jun 9, 2016

Appl. No.:

15/735133

Inventors:

- New York NY, US
- Emeryville CA, US
Andres Lopez-Albaitero - New York NY, US
Cheng Liu - Emeryville CA, US
Su Yan - State College PA, US
Jingyi Xiang - Walnut Creek CA, US
Hong Liu - El Sobrante CA, US

International Classification:

C07K 16/46
C07K 16/08
C07K 16/28
G01N 33/68

Abstract:

Described herein are antibodies, fragments thereof and multi-specific binding agents that bind an Epstein-Barr virus (EBV) latent membrane protein 2 (LMP2) peptide presented by HLA class I molecules, in particular, HLA-A02. Also provided herein are methods of using the same or compositions thereof for the detection, prevention and/or therapeutic treatment of diseases characterized by expression of an EBV-LMP2 peptide presented by HLA-A02, in particular, Burkit's lymphoma, Hodgkin's lymphoma and nasopharyngeal carcinoma.

US Patent:

20160280796, Sep 29, 2016

Filed:

Nov 7, 2014

Appl. No.:

15/034782

Inventors:

- New York NY, US
- Emeryville CA, US
Tao Dao - New York NY, US
Su Yan - State College PA, US
Cheng Liu - Oakland CA, US

International Classification:

C07K 16/32
C07K 16/28

Abstract:

Disclosed herein is a bi-specific form of a T cell receptor mimic (TCRm) mAb with reactivity to human immune effector cell antigen and a WT1 peptide/HLA-A epitope. This antibody selectively bound to leukemias and solid tumor cells expressing WT1 and HLA-A as well as activated resting human T cells to release interferon-(IFN-γ) and to kill the target cancer cells in vitro. Importantly, the antibody mediated autologous T cell proliferation and directed potent cytotoxicity against fresh ovarian cancer cells. Therapeutic activity in vivo of the antibody was demonstrated in NOD SCID SCID Yc* (NSG) mice with three different human cancers expressing WT1/HLA-A2 including disseminated Ph+ acute lymphocytic leukemia (ALL), disseminated acute myeloid leukemia, and peritoneal mesothelioma. In both of the leukemia xenograft models, mice that received the antibody and T cells also showed longer survival and delayed limb paralysis. Also provided are methods for stimulating a primary T cell response comprising stimulating cytotoxic T cells against a first tumor antigen and a secondary T cell response comprising stimulating effector T cells and/or memory T cells against a first tumor antigen and/or against a second tumor antigen using the bi-specific antibodies described herein.

US Patent:

20140294841, Oct 2, 2014

Filed:

Apr 2, 2012

Appl. No.:

14/008447

Inventors:

David A. Scheinberg - New York NY, US
Tao Dao - New York NY, US
Cheng Liu - Oakland CA, US
Su Yan - State College PA, US

Assignee:

EUREKA THERAPEUTICS, INC. - Emeryville CA
MEMORIAL SLOAN-KETTERING CANCER CENTER - New York NY

International Classification:

C07K 16/32
G01N 33/574

US Classification:

4241381, 4241781, 435 71, 435330, 435375, 4353201, 514 44 R, 5303873, 5303877, 5303913, 5303917, 536 2353

Abstract:

The present invention provides antigen binding proteins that specifically bind to Wilms' tumor protein (WT1), including humanized, chimeric and fully human antibodies against WT1, antibody fragments, chimeric antigen receptors (CARs), fusion proteins, and conjugates thereof. The antigen binding proteins and antibodies bind to HLA-A0201-restricted WT1 peptide. Such antibodies, fragments, fusion proteins and conjugates thereof are useful for the treatment of WT1 associated cancers, including for example, breast cancer, ovarian cancer, prostate cancer, chronic myelocytic leukemia, multiple myeloma, acute lymphoblastic leukemia (ALL), acute myeloid/myelogenous leukemia (AML) and myelodysplastic syndrome (MDS). In more particular embodiments, the anti-WT1/A antibodies may comprise one or more framework region amino acid substitutions designed to improve protein stability, antibody binding and/or expression levels.